[Endometrial carcinomas and precursor lesions--new aspects]

Area of Science:

• Gynecologic Oncology
• Pathology
• Molecular Biology

Context:

• Endometrial carcinomas present distinct clinicopathological and molecular features, necessitating precise classification.
• Current understanding separates these tumors into Type I (e.g., endometrioid) and Type II (e.g., serous, clear cell) categories.
• Precursor lesions like atypical hyperplasia and endometrial intraepithelial carcinoma (EIC) are identified for some subtypes.

Purpose:

• To delineate the distinct characteristics of Type I and Type II endometrial carcinomas.
• To highlight the importance of accurate tumor typing for prognostic assessment.
• To emphasize the clinical significance of identifying serous carcinoma components.

Summary:

• Endometrial carcinomas are broadly classified into Type I and Type II, exhibiting significant differences in microscopy, immunohistochemistry, molecular pathology, and clinical presentation.
• Type I tumors, including endometrioid and mucinous carcinomas, are associated with hyperestrogenism. Type II prototypes are serous and clear cell carcinomas.
• While precursor lesions are known for endometrioid (atypical hyperplasia) and serous (EIC) carcinomas, none is identified for clear cell carcinoma. Immunohistochemical markers aid in differentiation.

Impact:

• Accurate classification, particularly the detection of a serous component, is vital for determining prognosis and guiding treatment strategies.
• Early identification of aggressive subtypes like serous carcinoma necessitates prompt and potentially more intensive interventions, including surgery and adjuvant therapies.
• This classification framework aids in understanding tumor behavior and optimizing patient management in endometrial cancer.